Be the first to like this
GlaxoSmithKline (NYSE: GSK) is one of the globe's biggest drug companies. The company generates more than $40 billion in annual sales and given its dividend yield is nearly 5%, its shares are often included in dividend investor's portfolios. Glaxo has a solid track record of dividend increases over the past five years; however, investors are right to wonder whether sliding sales tied to patent expiration may put Glaxo's streak in jeopardy.
In the following slideshow you'll learn whether I think Glaxo's dividend is safe and see how Glaxo's dividend matches up to its new consumer goods joint venture partner Novartis (NYSE: NVS) and its competitor AstraZeneca (NYSE: AZN).
Clipping is a handy way to collect important slides you want to go back to later.